Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Kymera Therapeutics Inc’s stock clocked out at $34.41, down -4.52% from its previous closing price of $36.04. In other words, the price has decreased by -$4.52 from its previous closing price. On the day, 0.66 million shares were traded. KYMR stock price reached its highest trading level at $36.15 during the session, while it also had its lowest trading level at $34.155.
Ratios:
To gain a deeper understanding of KYMR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.55 and its Current Ratio is at 8.55. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on December 10, 2024, initiated with a Buy rating and assigned the stock a target price of $60.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Market Perform rating and target price of $55.
Wells Fargo Upgraded its Equal Weight to Overweight on December 02, 2024, while the target price for the stock was maintained at $57.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 06 ’25 when Chiniara Ellen sold 3,129 shares for $41.75 per share. The transaction valued at 130,645 led to the insider holds 54,826 shares of the business.
Chiniara Ellen bought 3,129 shares of KYMR for $130,135 on Jan 06 ’25. On Dec 02 ’24, another insider, Esposito Pamela, who serves as the Director of the company, sold 2,500 shares for $49.00 each. As a result, the insider received 122,500 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 2228573952 and an Enterprise Value of 1766834048. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.45 while its Price-to-Book (P/B) ratio in mrq is 2.50. Its current Enterprise Value per Revenue stands at 20.178 whereas that against EBITDA is -9.275.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.19, which has changed by -0.022511542 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $53.27, while it has fallen to a 52-week low of $29.24. The 50-Day Moving Average of the stock is -17.07%, while the 200-Day Moving Average is calculated to be -17.45%.
Shares Statistics:
It appears that KYMR traded 478.52K shares on average per day over the past three months and 403670 shares per day over the past ten days. A total of 64.75M shares are outstanding, with a floating share count of 54.99M. Insiders hold about 15.09% of the company’s shares, while institutions hold 95.08% stake in the company. Shares short for KYMR as of 1738281600 were 7690384 with a Short Ratio of 17.45, compared to 1735603200 on 8772474. Therefore, it implies a Short% of Shares Outstanding of 7690384 and a Short% of Float of 13.260000999999999.
Earnings Estimates
The current rating of Kymera Therapeutics Inc (KYMR) reflects the combined expertise of 16.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.76, with high estimates of -$0.31 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$2.13 and -$3.12 for the fiscal current year, implying an average EPS of -$2.84. EPS for the following year is -$3.23, with 17.0 analysts recommending between -$1.7 and -$4.36.
Revenue Estimates
In the current quarter, 18 analysts expect revenue to total $14.81M. It ranges from a high estimate of $65.7M to a low estimate of $2M. As of the current estimate, Kymera Therapeutics Inc’s year-ago sales were $47.88M
A total of 20 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $105.3M, while the lowest revenue estimate was $42M, resulting in an average revenue estimate of $53.83M. In the same quarter a year ago, actual revenue was $78.59MBased on 21 analysts’ estimates, the company’s revenue will be $69.22M in the next fiscal year. The high estimate is $163M and the low estimate is $15M.
